Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Found vs NuBloom

Found
Graded #14

Higher grade

vs+14.5
NuBloom
Graded #139

Lower grade

The verdict

Found takes it — 83.5/100 to 69/100.

Found grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The broadest medication bench on the board — compounded, brand-name and oral orforglipron — priced off a membership rather than a sticker.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFound +6
78
72
Dose & formulationFound +40
94
54
Clinical oversightFound +4
86
82
Labs & monitoringFound +21
82
61
FulfillmentNuBloom +1
84
85
Contract termsFound +15
70
55
Found · left barNuBloom · right bar

The numbers

MetricFoundNuBloom
WeighScore83.5/10069/100
GradeBC
Scorecard rank#14#139
SemaglutideCompounded from $99/mo$149/mo (2.4 mg dose, compounded)
TirzepatideCompounded from $99/mo$279/mo (15 mg dose, compounded)
CoverageAll 50 states49 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Found

Graded #14 · B

Strengths

  • Widest medication list on this board — compounded semaglutide and tirzepatide, brand Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda and Victoza, plus oral Foundayo (orforglipron) and Rybelsus
  • Flat pricing as the dose increases, so a titration does not raise the monthly cost
  • Bills insurance for the clinical visits — the site states most members pay under $30 per visit
  • Runs a dedicated GLP-1 microdose programme for people who want a lower starting dose

Where it loses points

  • The $99/mo headline is a longer-plan floor — Found's own FAQ says 3, 6 and 12-month plans are what keep the monthly cost down, so month-to-month costs meaningfully more
  • Medication cost is separate from the membership and clinical care, so no advertised figure is the all-in number
  • The homepage insurance selector lists roughly 41 states, not 50 — coverage is narrower than the service footprint
  • Compounded medication is not FDA-approved the way brand Wegovy or Zepbound are
NuBloom

Graded #139 · C

Strengths

  • Transparent, openly published pricing: compounded semaglutide $149/mo and tirzepatide $279/mo as flexible month-to-month subscriptions
  • Founded and medically led by a named physician (Dr. Marianne Pinkston Mueller, family/integrative medicine, 25+ years)
  • Whole-person model pairs GLP-1s with hormone, gut-health and longevity care plus in-depth lab testing
  • State coverage published openly: 49 states listed on the site (all except Mississippi)
  • Optional 90-day 1:1 coaching program with weekly meetings and unlimited text support ($599/mo)

Where it loses points

  • Compounding pharmacy partners are not named anywhere on the site — a transparency gap
  • NuBloom's own LegitScript/PCAB status is not displayed; only its telehealth partner is certified
  • Compounded medications are not FDA-approved; one FAQ loosely calls them 'FDA-approved,' contradicting the product pages
  • All sales are final and medical consult fees are non-refundable; no returns on prescription products
  • Disputes go to binding individual arbitration; the Terms' governing-law state is left as an unfilled '[STATE]' placeholder

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard